Trials / Conditions / Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

23 registered clinical trials studyying Primary Mediastinal Large B-cell Lymphoma (PMBCL) — 14 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579	Vironexis Biotherapeutics Inc.	Phase 1 / Phase 2
Recruiting	CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735	British Columbia Cancer Agency	Phase 1
Recruiting	SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265	Verismo Therapeutics	Phase 1
Enrolling By Invitation	CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486	University of Maryland, Baltimore	Phase 1
Recruiting	A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma NCT06486051	Malaghan Institute of Medical Research	Phase 2
Recruiting	P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies NCT06014762	Poseida Therapeutics, Inc.	Phase 1
Recruiting	Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors NCT05934084	Fondazione Italiana Linfomi - ETS	N/A
Recruiting	Pembro Plus CAR T-cell Therapy in R/R in PMBCL NCT05934448	Jennifer Crombie, MD	Phase 2
Recruiting	CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319	Marcela V. Maus, M.D.,Ph.D.	Phase 1
Recruiting	Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients NCT07473167	TICAROS Co., Ltd.	Phase 1 / Phase 2
Active Not Recruiting	Primary Mediastinal Large B-cell Lymphoma With CNS Involvement NCT06024694	IRCCS San Raffaele	—
Recruiting	Bio-CAR-T BS Study NCT05366569	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	—
Active Not Recruiting	Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma NCT04526834	Tessa Therapeutics	Phase 1
Completed	A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed NCT04875195	Merck Sharp & Dohme LLC	Phase 2
Recruiting	Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients NCT04836507	Curocell Inc.	Phase 1 / Phase 2
Active Not Recruiting	Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy NCT04745559	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Completed	CAR T Cell Therapy Related Cardiovascular Outcomes NCT05130489	University College London Hospitals	—
Unknown	Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymp NCT04600947	Taizhou HoudeAoke Biomedical Co., Ltd.	Phase 2
Recruiting	CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520	Medical College of Wisconsin	Phase 1 / Phase 2
Recruiting	Italian Observational Study on CAR-T Therapy for Lymphoma NCT06339255	Paolo Corradini	—
Completed	Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study NCT05162170	Fondazione Italiana Linfomi - ETS	—
Active Not Recruiting	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma NCT03625037	Genmab	Phase 1 / Phase 2
Approved For Marketing	Expanded Access Program for Epcoritamab NCT05733650	Genmab	—